Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Positive Controlled Phase III Clinical Trial of ZX-7101A Tablets to Evaluate the Safety and Efficacy in the Treatment of Uncomplicated Influenza in Children Aged 5-11 Years

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Positive Controlled Phase III Clinical Trial of ZX-7101A Tablets to Evaluate the Safety and Efficacy in the Treatment of Uncomplicated Influenza in Children Aged 5-11 Years

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Masiloxavir (Primary) ; Oseltamivir
  • Indications Influenza virus infections
  • Focus Pharmacokinetics; Registrational
  • Sponsors Nanjing Zenshine Pharmaceuticals

Most Recent Events

  • 13 Aug 2025 Status changed from recruiting to discontinued.
  • 18 Feb 2025 Planned number of patients changed from 12 to 180.
  • 18 Feb 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top